Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17922691 | 0.88 | ADORA2A (0.48) | NPSR1KDM4AMRGPRX4POLBMAPK1 | |
| SCHEMBL3980110 | 0.88 | GRM2 (0.46) | NPSR1KDM4AKDM4EPOLBMAPK1 | |
| SCHEMBL18765320 | 0.86 | NQO2 (0.49) | NPSR1KDM4EALOX15TSHRACMSD | |
| SCHEMBL31098475 | 0.85 | KDM4A (0.43) | NPSR1KDM4AKDM4EPOLBMAPK1 | |
| SCHEMBL15436036 | 0.84 | CYP1A2 (0.56) | NPSR1KDM4AKDM4EPOLBMAPK1 | |
| SCHEMBL7946055 | 0.83 | KDM4A (0.42) | NPSR1KDM4APOLBMAPK1ATM | |
| SCHEMBL26616825 | 0.83 | NPSR1 (0.49) | NPSR1KDM4APOLBMAPK1ATM | |
| SCHEMBL112919 | 0.83 | NPSR1 (0.49) | NPSR1KDM4APOLBMAPK1ATM | |
| SCHEMBL16551970 | 0.82 | KDM4A (0.41) | NPSR1KDM4ACA12CA1CKS1B | |
| SCHEMBL29510880 | 0.82 | NPSR1 (0.47) | NPSR1KDM4APOLBMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563245-B | Substituted pyrrolidines and their use in medicine | 广东东阳光药业股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-113563245-A | Substituted pyrrolidine compounds and application thereof in medicines | 广东东阳光药业有限公司 | 2021-10-29 | — | — | CN | disclosed |
| EP-3042913-B1 | CYCLIC PEPTIDE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU GUANYU BIO MEDICAL CO LTD (CN) | 2019-03-20 | — | — | EP | disclosed |
| EP-3042913-A1 | CYCLIC PEPTIDE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Hangzhou Guanyu Bio-Medical Co., Ltd (CN) | 2016-07-13 | — | — | EP | disclosed |
| US-7879853-B2 | tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer | BAYER SCHERING PHARMA AG (DE) | 2011-02-01 | — | — | US | disclosed |
| EP-1763526-B1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AG (DE) | 2009-06-24 | — | — | EP | disclosed |
| WO-2009056886-A1 | PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF FGFR ACTIVITY | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | WO | disclosed |
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | ATLANTA PHARMA AG (DE) | 2007-09-06 | — | — | US | disclosed |
| EP-1763526-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Altana Pharma AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000589-A1 | 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS | ALTANA PHARMA AG (DE) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208034-A1 | 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors | CDK2, DCK, DTYMK | NPSR1 4348/4885KDM4A 2205/4885KDM4E 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.